Chugai Pharmaceutical Co., Ltd.
Wednesday, June 05, 2024
Multiple Therapeutics
Company Presentation Theater 2
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/
Company Website:
https://www.chugai-pharm.co.jp/english
Lead Product in Development:
GYM329: Anti-latent myostatin sweeping antibody
AMY109: Anti-IL-8 recycling antibody
NXT007: Anti-coagulation factor Ixa/X bispecific antibody
LUNA18: RAS inhibitor, Mid-size molecule
ERY974: Anti-Glypican-3/CD3 bispecific antibody
STA551: Anti-CD137 agonistic Switch antibody
SOF10: Anti-latent TGF-β1 monoclonal antibody
ALPS12: Anti-DLL3/CD3/CD137 trispecific antibody
SAIL66: AntiCLDN6/CD3/CD137 trispecific antibody
ROSE12
SPYK04
DONQ52: Anti-HLA-DQ2.5/gluten peptides multispecific antibody
RAY121
REVN24
Exchange
Tokyo
Ticker
4519
Company HQ City
Tokyo
Company HQ State
*
Company HQ Country
Japan
CEO/Top Company Official
Dr. Osamu Okuda, Representative Director, President & CEO
Development Phase of Primary Product
Multiple Products in Market
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())